Meeting
2022 ASCO Annual Meeting
Targetable genomic mutations in young women with advanced breast cancer.
Authors
Norin Ansari
Yale New Haven Hospital, New Haven, CT
Norin Ansari , Lucy Gao , Ethan Sokol , Smruthy Sivakumar , Richard S.P. Huang , Maureen Pelletier , Mia Alyce Levy , Dean C. Pavlick , Natalie Danziger , Jeffrey S. Ross , Maryam B. Lustberg , Mariya Rozenblit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1027)
DOI
10.1200/JCO.2022.40.16_suppl.1027
Abstract #
1027
Poster Bd #
405
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.
First Author: Peter Cornelius
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2016 ASCO Annual Meeting
SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.
First Author: Fabrice Andre